• ROS-Mediated Metabolic Rewiring in Melanoma Under BRAF Inhib

  2026-06-02

  Cesi et al. reveal that BRAF inhibitor treatment in melanoma cells triggers reactive oxygen species (ROS) production, which in turn activates pyruvate dehydrogenase kinases (PDKs) and suppresses oxidative metabolism by phosphorylating and inactivating PDH. This mechanistic insight into metabolic adaptation offers new avenues for targeting drug-resistant melanoma.

• SMYD2 Inhibition Mitigates Cisplatin-Induced Renal Fibrosis

  2026-06-01

  The reference study demonstrates that pharmacological inhibition of SMYD2, using selective inhibitors such as LLY-507, protects against cisplatin-induced renal fibrosis and inflammation in experimental chronic kidney disease models. These findings reveal SMYD2 as a mechanistically relevant target for attenuating fibrosis and highlight the translational value of selective SMYD2 inhibitors for renal, oncologic, and fibrosis research.

• GSTA1-Mediated Glutathione Depletion Drives α-Amanitin Hepat

  2026-06-01

  This study uncovers a paradoxical mechanism in which the hepatic antioxidant enzyme GSTA1, upon upregulation by α-amanitin, accelerates glutathione depletion and intensifies oxidative stress, worsening liver injury. These findings identify GSTA1 as a promising therapeutic target and biomarker for acute hepatotoxicity, with implications for experimental design in redox and glutaminase pathway research.

• Canagliflozin Hemihydrate: Precision SGLT2 Inhibition in Res

  2026-05-31

  Canagliflozin hemihydrate delivers unmatched selectivity for SGLT2, empowering metabolic and diabetes researchers to dissect renal glucose reabsorption without off-target mTOR effects. Its solubility, protocol flexibility, and high purity make it a go-to reagent for robust experimental design.

• Silybin Chemistry: Advances in Milk Thistle Flavonolignan Re

  2026-05-30

  The comprehensive review by Křen et al. dissects the chemistry, structure, and derivatization of silybin, the principal bioactive constituent of milk thistle extract. Their work clarifies the stereochemistry, synthetic strategies, and antioxidant mechanisms of silybin, underpinning its application in oxidative stress and cancer research.

• IGF2BP3–FZD1/7 Axis Drives Stemness and Carboplatin Resistan

  2026-05-29

  This study identifies IGF2BP3 as a key m6A reader that stabilizes FZD1/7 transcripts, sustaining cancer stemness and carboplatin resistance in triple-negative breast cancer (TNBC). Pharmacological targeting of this axis sensitizes TNBC stem-like cells to platinum-based chemotherapy, offering a mechanistically grounded strategy for overcoming chemoresistance.

• Canagliflozin (hemihydrate): Reliable SGLT2 Inhibitor for Me

  2026-05-29

  This article addresses key laboratory challenges in cell viability and metabolic pathway studies, focusing on how Canagliflozin (hemihydrate) (SKU C6434) supports reproducible, high-quality research. By grounding recommendations in published data and highlighting workflow-specific advantages, it guides biomedical researchers toward optimal experimental outcomes using validated SGLT2 inhibition.

• HOBt (1-Hydroxybenzotriazole): Enabling Precision Amide Synt

  2026-05-28

  Explore how HOBt (1-Hydroxybenzotriazole) advances amide bond formation and peptide synthesis, with a deep dive into its mechanistic role and critical impact on the synthesis of complex bioactive molecules. This article uniquely connects HOBt’s technical nuances to real-world drug development strategies.

• Adipogenic Transdifferentiation Limits PDAC Metastasis via C

  2026-05-28

  This study demonstrates that enforced adipogenic transdifferentiation reprograms EMT-high pancreatic ductal adenocarcinoma (PDAC) cells into post-mitotic, adipocyte-like states, suppressing metastatic potential and tumor growth. The findings highlight a novel, lineage-conversion approach to curbing PDAC progression, with implications for differentiation therapy in aggressive epithelial cancers.

• Epoxomicin: Selective Irreversible Proteasome Inhibitor for

  2026-05-27

  Epoxomicin is a potent, selective, and irreversible proteasome inhibitor widely used in ubiquitin-proteasome pathway research. Its α',β'-epoxyketone moiety enables covalent binding to 20S proteasome catalytic residues, with nanomolar IC50 for chymotrypsin-like activity. Epoxomicin underpins experimental models of protein degradation, inflammation, and neurodegenerative diseases.

• Dual-Action Inhibitors Accelerate p38α MAPK Dephosphorylatio

  2026-05-27

  The referenced study uncovers that certain kinase inhibitors not only block p38α MAPK activity but also promote its dephosphorylation by stabilizing a phosphatase-accessible conformation. This dual-action mechanism provides new insights for achieving specificity and potency in kinase-targeted research and drug development.

• AT-406 (SM-406): Orally Bioavailable IAP Antagonist in Oncol

  2026-05-26

  AT-406 (SM-406) is a potent, orally bioavailable inhibitor of apoptosis proteins (IAPs) that activates apoptosis pathways in cancer cells and sensitizes tumors to chemotherapeutics. Extensive in vitro and in vivo evidence supports its utility in oncology research, especially for ovarian and breast cancer models.

• Notch Inhibition Boosts Immunotherapy in Triple-Negative Bre

  2026-05-26

  Shen et al. demonstrate that targeting the Notch pathway can reprogram the tumor immune microenvironment in triple-negative breast cancer (TNBC), enhancing the efficacy of immune checkpoint blockade (ICB). Their findings identify Notch-driven cytokine signaling as a therapeutic vulnerability for improving immunotherapy outcomes in aggressive breast cancers.

• Canagliflozin Remodels Mitochondria in Diabetic Mouse Kidney

  2026-05-25

  This study demonstrates that Canagliflozin, a selective SGLT2 inhibitor, not only lowers glucose but also induces structural and functional improvements in proximal tubular mitochondria of hypertensive–diabetic mice. These findings expand understanding of SGLT2 inhibition's renal protective effects, highlighting mitochondrial remodeling as a mechanistic link with implications for advanced kidney disease research.

• Fulvestrant (ICI 182,780): Mechanistic Benchmarks in ER+ Bre

  2026-05-25

  Fulvestrant (ICI 182,780) is a potent estrogen receptor antagonist that enables post-translational MDM2 protein degradation and enhances chemotherapy sensitivity in ER-positive breast cancer models. Its high-affinity ERα binding and receptor downregulation underpin its utility in advanced breast cancer research and therapy.

8644 records 11/577 page Previous Next First page 上5页 1112131415 下5页 Last page